{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T02:33:19Z","timestamp":1648780399298},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,5,19]],"date-time":"2010-05-19T00:00:00Z","timestamp":1274227200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s00393-010-0630-4","type":"journal-article","created":{"date-parts":[[2010,5,17]],"date-time":"2010-05-17T15:23:40Z","timestamp":1274109820000},"page":"483-485","source":"Crossref","is-referenced-by-count":0,"title":["Spielt TNF in der Pathogenese von soliden Tumoren eine Rolle?"],"prefix":"10.1007","volume":"69","author":[{"given":"H.","family":"Bastian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.-R.","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,19]]},"reference":[{"key":"630_CR1","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","volume":"72","author":"Carswell","year":"1975","unstructured":"Carswell EA, Old LJ, Kassel RL et al (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72:3666\u20133670","journal-title":"Proc Natl Acad Sci U S A"},{"key":"630_CR2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc2628","volume":"9","author":"Balkwill","year":"2009","unstructured":"Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9:361\u2013371","journal-title":"Nat Rev Cancer"},{"key":"630_CR3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2174\/156800908783769346","volume":"8","author":"Daniel","year":"2008","unstructured":"Daniel D, Wilson NS (2008) Tumor necrosis factor: renaissance as a cancer therapeutic? Curr Cancer Drug Targets 8:124\u2013131","journal-title":"Curr Cancer Drug Targets"},{"key":"630_CR4","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.4049\/jimmunol.164.12.6193","volume":"164","author":"Eissner","year":"2000","unstructured":"Eissner G, Kirchner S, Lindner H et al (2000) Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J Immunol 164:6193\u20136198","journal-title":"J Immunol"},{"key":"630_CR5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"Tracey","year":"2008","unstructured":"Tracey D, Klareskog L, Sasso EH et al (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117:244\u2013279","journal-title":"Pharmacol Ther"},{"key":"630_CR6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI11830","volume":"107","author":"Tak","year":"2001","unstructured":"Tak PP, Firestein GS (2001) NF-kappa b: a key role in inflammatory diseases. J Clin Invest 107:7\u201311","journal-title":"J Clin Invest"},{"key":"630_CR7","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/annonc\/mdn054","volume":"19","author":"Brown","year":"2008","unstructured":"Brown ER, Charles KA, Hoare SA et al (2008) A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol 19:1340\u20131346","journal-title":"Ann Oncol"},{"key":"630_CR8","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1158\/1078-0432.CCR-04-0730","volume":"10","author":"Madhusudan","year":"2004","unstructured":"Madhusudan S, Foster M, Muthuramalingam SR et al (2004) A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res 10:6528\u20136534","journal-title":"Clin Cancer Res"},{"key":"630_CR9","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1200\/JCO.2005.04.127","volume":"23","author":"Madhusudan","year":"2005","unstructured":"Madhusudan S, Muthuramalingam RS, Braybrooke JP et al (2005) Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J Clin Oncol 23:5950\u20135959","journal-title":"J Clin Oncol"},{"key":"630_CR10","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1200\/JCO.2007.11.2136","volume":"25","author":"Harrison","year":"2007","unstructured":"Harrison ML, Obermueller E, Maisey NR et al (2007) Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 25:4542\u20134549","journal-title":"J Clin Oncol"},{"key":"630_CR11","unstructured":"Center for Drug Evaluation and Research Information on Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). http:\/\/www.fda.gov\/Drugs\/drugsafety\/postmarketdrugsafetyinformationforpatientsandproviders\/ucm109340.htm"},{"key":"630_CR12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","volume":"370","author":"Grulich","year":"2007","unstructured":"Grulich AE, Leeuwen MT van, Falster MO, Vajdic CM (2007) Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370:59\u201367","journal-title":"Lancet"},{"key":"630_CR13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/ard.43.2.128","volume":"43","author":"Prior","year":"1984","unstructured":"Prior P, Symmons DP, Hawkins CF et al (1984) Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis 43:128\u2013131","journal-title":"Ann Rheum Dis"},{"key":"630_CR14","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","volume":"54","author":"Baecklund","year":"2006","unstructured":"Baecklund E, Iliadou A, Askling J et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692\u2013701","journal-title":"Arthritis Rheum"},{"key":"630_CR15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","volume":"317","author":"Baecklund","year":"1998","unstructured":"Baecklund E, Ekbom A, Spar\u00e9n P et al (1998) Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 317:180\u2013181","journal-title":"BMJ"},{"key":"630_CR16","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1002\/art.24941","volume":"60","author":"Askling","year":"2009","unstructured":"Askling J et al (2009) Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 60:3180\u20133189","journal-title":"Arthritis Rheum"},{"key":"630_CR17","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar2904","volume":"12","author":"Strangfeld","year":"2010","unstructured":"Strangfeld A, Hierse F, Rau R et al (2010) Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 12:R5","journal-title":"Arthritis Res Ther"},{"key":"630_CR18","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1136\/ard.2008.102103","volume":"68","author":"Burmester","year":"2009","unstructured":"Burmester GR, Mease P, Dijkmans BAC et al (2009) Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 68:1863\u20131869","journal-title":"Ann Rheum Dis"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-010-0630-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-010-0630-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-010-0630-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T16:36:01Z","timestamp":1559061361000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-010-0630-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,19]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["630"],"URL":"https:\/\/doi.org\/10.1007\/s00393-010-0630-4","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,19]]}}}